Inventiva (NASDAQ:IVA) Shares Down 7% – Here’s What Happened

Shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA) traded down 7% on Wednesday . The company traded as low as $4.36 and last traded at $4.3440. Approximately 1,059,394 shares traded hands during trading, an increase of 57% from the average session volume of 676,366 shares. The stock had previously closed at $4.67.

Wall Street Analyst Weigh In

A number of brokerages have commented on IVA. Weiss Ratings reiterated a “sell (d-)” rating on shares of Inventiva in a report on Friday, July 17th. Cantor Fitzgerald started coverage on shares of Inventiva in a report on Friday, July 17th. They issued an “overweight” rating on the stock. Three research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $15.38.

Inventiva Price Performance

The firm’s fifty day simple moving average is $4.55 and its 200 day simple moving average is $5.00.

Institutional Trading of Inventiva

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Engineers Gate Manager LP lifted its holdings in Inventiva by 155.5% in the second quarter. Engineers Gate Manager LP now owns 71,116 shares of the company’s stock valued at $269,000 after acquiring an additional 43,280 shares during the period. Seven Fleet Capital Management LP acquired a new stake in shares of Inventiva during the 1st quarter worth approximately $1,111,000. Virtu Financial LLC purchased a new position in shares of Inventiva during the 4th quarter valued at approximately $60,000. ADAR1 Capital Management LLC purchased a new position in shares of Inventiva during the 4th quarter valued at approximately $12,601,000. Finally, XTX Topco Ltd acquired a new position in shares of Inventiva in the 4th quarter valued at $84,000. 19.06% of the stock is owned by institutional investors and hedge funds.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical?stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.